Cyclophosphamide
Extranodal Nasal NK/T Cell Lymphoma
Explore 50 assets in Extranodal Nasal NK/T Cell Lymphoma →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Tarapeutics Science Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07639879CT.gov TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07276737CT.gov Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT05941156CT.gov Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | — | Unknown | — | — | — |
NCT05208853CT.gov An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | — | Unknown | — | — | — |
NCT04004637CT.gov CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia | — | Unknown | — | — | — |
NCT03728972CT.gov Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type | — | Active Not Recruiting | — | — | — |
NCT03012620CT.gov Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types | — | Completed | — | — | — |
NCT01667289CT.gov Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma | — | Terminated | — | — | — |
NCT04484506CT.gov Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma | — | Unknown | — | — | — |
NCT01466881CT.gov Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT01384513CT.gov A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | — | Completed | — | — | — |
NCT01129180CT.gov Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | — | Completed | — | — | — |
NCT01044745CT.gov Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | — | Terminated | — | — | — |
NCT00994500CT.gov Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | — | Completed | — | — | — |
NCT01445535CT.gov Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | — | Completed | — | — | — |
NCT00536601CT.gov High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Extranodal Nasal NK/T Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Tarapeutics Science Inc. | P3 | BB · 66 |
| Pegaspargase | CStone Pharmaceuticals | P4 | BBB |
| Dexasone | Mingzhi Zhang | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Centre, Singapore | P4 | BBB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
| Etoposide | Tarapeutics Science Inc. | P4 | BB |
| Lenalidomide | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BB |
| Asparaginase | National Cancer Centre, Singapore | P3 | BB |
+42 more in the Extranodal Nasal NK/T Cell Lymphoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Extranodal Nasal NK/T Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-extranodal-nasal-nkt-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →